These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 6083957)

  • 41. Heparin cofactor II determination--levels in normals and patients with hereditary antithrombin III deficiency and disseminated intravascular coagulation.
    Tran TH; Duckert F
    Thromb Haemost; 1984 Oct; 52(2):112-6. PubMed ID: 6395434
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients.
    Wada H; Mori Y; Okabayashi K; Gabazza EC; Kushiya F; Watanabe M; Nishikawa M; Shiku H; Nobori T
    Am J Hematol; 2003 Jan; 72(1):1-7. PubMed ID: 12508260
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Clinical importance of the determination of antithrombin III by the use of a chromogenic substrate, in cases of disseminated intravascular coagulation and of acute hepatic insufficiency].
    Carmignoto F; Schivo P; Plebani M; Pengo V; Piccini P; Ceriotti G
    Quad Sclavo Diagn; 1981 Jun; 17(2):172-81. PubMed ID: 7267980
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antithrombin III in Sepsis. New evidences and open questions.
    Ostermann H
    Minerva Anestesiol; 2002 May; 68(5):445-8. PubMed ID: 12029261
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Current views on the therapeutic use of heparin and antithrombin III in disseminated intravascular coagulation].
    Sobczyk J; Swietliński J; Podleśny-Owsińska T
    Pol Tyg Lek; 1989 Oct 2-16; 44(40-42):896-8. PubMed ID: 2487947
    [No Abstract]   [Full Text] [Related]  

  • 46. [The physiological inhibitors of blood coagulation. 1. Antithrombin III (AT III)].
    Kase F; Pospísil J
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1983; 110(3):337-49. PubMed ID: 6194066
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Abnormality of blood coagulation before onset of DIC--risk factors for DIC].
    Wada H; Takagi M; Suzuki H; Deguchi K; Shirakawa S
    Rinsho Byori; 1990 Jul; Suppl 86():134-41. PubMed ID: 2232234
    [No Abstract]   [Full Text] [Related]  

  • 48. On the clinical significance of acquired antithrombin deficiency.
    Sørum Y; Handeland GF; Abildgaard U
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(6):797-805. PubMed ID: 6083956
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Diagnosis of defibrination syndromes in infectious pathology].
    Samama M
    Ann Biol Clin (Paris); 1984; 42(1):41-5. PubMed ID: 6731953
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [[Antithrombin III concentrates in the treatmetn of sepsis and septic shock: indictions, limits and future prospects] ].
    Baudo F; de Cataldo F
    Minerva Anestesiol; 2000 Nov; 66(11 Suppl 1):3-23. PubMed ID: 11213542
    [TBL] [Abstract][Full Text] [Related]  

  • 51. International Society on Thrombosis and Haemostasis score for overt disseminated intravascular coagulation predicts organ dysfunction and fatality in sepsis patients.
    Voves C; Wuillemin WA; Zeerleder S
    Blood Coagul Fibrinolysis; 2006 Sep; 17(6):445-51. PubMed ID: 16905947
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Studies on antithrombin III. II. The role for antithrombin III (ATIII) in the control of disseminated intravascular coagulation (DIC). (The effect of the administration of ATIII concentrates in experimental DIC and in clinical DIC) (author's transl)].
    Takahashi K
    Nihon Ketsueki Gakkai Zasshi; 1980 Oct; 43(5):889-97. PubMed ID: 6940410
    [No Abstract]   [Full Text] [Related]  

  • 53. Plasmapheresis in severe septic shock with disseminated intravascular coagulation.
    Zilow EP; Selle B; Zilow G
    Beitr Infusionsther Transfusionsmed; 1994; 32():374-7. PubMed ID: 9422119
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Determination of plasma soluble fibrin using a new ELISA method in patients with disseminated intravascular coagulation.
    Okajima K; Uchiba M; Murakami K; Okabe H; Takatsuki K
    Am J Hematol; 1996 Mar; 51(3):186-91. PubMed ID: 8619398
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Coagulation and fibrinolysis in multiple trauma after early heparinizing.
    Trentz O; Barthels M; Trentz OA; Oestern HJ; Hempelmann G; Kolbow H
    Adv Shock Res; 1979; 2():103-10. PubMed ID: 262799
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diagnosis of pre-disseminated intravascular coagulation stage with hemostatic molecular markers. The Mie DIC Study Group.
    Wada H; Wakita Y; Nakase T; Shimura M; Hiyoyama K; Nagaya S; Mori Y; Deguchi K; Shiku H
    Pol J Pharmacol; 1996; 48(2):225-8. PubMed ID: 9112656
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protection against disseminated intravascular coagulation and death by antithrombin-III in the Escherichia coli endotoxemic rat.
    Emerson TE; Fournel MA; Leach WJ; Redens TB
    Circ Shock; 1987; 21(1):1-13. PubMed ID: 3545529
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic modalities to ameliorate endotoxin induced DIC in the rats.
    Bahrami S; Paul E; Redl H; Schlag G
    Prog Clin Biol Res; 1989; 308():977-82. PubMed ID: 2780743
    [No Abstract]   [Full Text] [Related]  

  • 59. [Assay for activity of heparin-antithrombin III complex during treatment of DIC with heparin and its clinical significance].
    Tomihara T; Shimazu C; Yasuda K; Kazama M; Abe T
    Rinsho Byori; 1986 Feb; 34(2):179-84. PubMed ID: 3702087
    [No Abstract]   [Full Text] [Related]  

  • 60. [Heparin, low molecular weight heparin, heparinoid, and antithrombin III therapy of disseminated intravascular coagulation].
    Nakagawa M
    Nihon Rinsho; 1993 Jan; 51(1):87-92. PubMed ID: 7679453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.